Glycyrrhetinic acid potently suppresses breast cancer invasion and metastasis by impairing the p38 MAPK-AP1 signaling axis

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 5, 2015, Pages 577-587

  Wang, Xiu Feng ^a,b   Zhou, Qian Mei ^a   Lu, Yi Yu ^a   Zhang, Hui ^a   Huang, Shuang ^a,c   Su, Shi Bing ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Fujian Academy of Traditional Chinese Medicine   (China)

^c MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Breast cancer; Glycyrrhetinic acid; Invasion; MMP; P38 MAPK

Indexed keywords

ACTIVATING PROTEIN 1; ANTINEOPLASTIC AGENT; GELATINASE A; GELATINASE B; GLYCYRRHETINIC ACID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN C JUN; SYNAPSIN I; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR FRA 1; UNCLASSIFIED DRUG; TRANSCRIPTION FACTOR AP 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; BREAST CANCER CELL LINE; CANCER INHIBITION; CANCER SIZE; CELL INVASION; CELL MIGRATION; CELL SURVIVAL; CONCENTRATION RESPONSE; CONSENSUS SEQUENCE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME REPRESSION; FEMALE; GLYCYRRHIZA; IC50; IN VITRO STUDY; LUNG METASTASIS; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; GLYCYRRHETINIC ACID; GLYCYRRHIZA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MICE; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; P38 MITOGEN-ACTIVATED PROTEIN KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84928495710     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1012156     Document Type: Article

References (43)

1. Dong S, Inoue A, Zhu Y, et al. Activation of rapid signaling pathways and the subsequent transcriptional regulation for the proliferation of breast cancer MCF 7 cells by the treatment withan extract of Glycyrrhiza glabra root. Food Chem Toxicol 2007;45:2470-8
2. Kim SC, Park SJ, Lee JR, et al. Cytoprotective activity of glycyrrhizae radix extract against arsenite induced cytotoxicity. eCAM 2008;2:165-71
3. Satomi Y, Nishino H, Shibata S. Glycyrrhetinic acid and related compounds induce G1 arrest and apoptosis in human hepatocellular carcinoma HepG2. Anticancer Res 2005;25:4043-7
4. Chadalapaka G, Jutooru I, McAlees A, et al. Structure-dependent inhibition of bladder and pancreatic cancer cell growth by 2-substituted glycyrrhetinic and ursolic acid derivatives. Bioorg Med Chem Lett 2008;18:2633-9
5. Hibasami H, Iwase H, Yoshioka K, et al. Glycyrrhetic acid (a metabolic substance and aglycon of glycyrrhizin) induces apoptosis in human hepatoma, promyelotic leukemia and stomach cancer cells. Int J Mol Med 2006;17:215-19
6. Abe H, Ohya N, Yamamoto KF, et al. Effects of glycyrrhizin and glycyrrhetinic acid on growth and melanogenesis in cultured B16 melanoma cells. Eur J Cancer Clin Oncol 1987;23:1549-55
7. Sharma G, Kar S, Palit S, et al. 18beta-glycyrrhetinic acid induces apoptosis through modulation of Akt/ FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J Cell Physiol 2012;227:1923-31
8. Shetty AV, Thirugnanam S, Dakshinamoorthy G, et al. 18alpha-glycyrrhetinic acid targets prostate cancer cells by down-regulating inflammation-related genes. Int J Oncol 2011;39:635-40
9. Yamaguchi H, Noshita T, Yu T, et al. Novel effects of glycyrrhetinic acid on the central nervous system tumorigenic progenitor cells: induction of actin disruption and tumor cell-selective toxicity. Eur J Med Chem 2010;45:2943-8
10. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis. Oncogene 2003;22:6524-36
11. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14
12. Scherer RL, McIntyre JO, Matrisian LM. Imaging matrix metalloproteinases in cancer. Cancer metastasis reviews 2008;27:679-90
13. Mohammad MA, Zeeneldin AA, Abd Elmageed ZY, et al. Clinical relevance of cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MT1- MMP) in human breast cancer tissue. Mol Cell Biochem 2012;366:269-75
14. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999;189:161-8
15. Kim TD, Song KS, Li G, et al. Activity and expression of urokinase-type plasminogen activator and matrix metalloproteinases in human colorectal cancer. BMC Cancer 2006;6:211
16. Matsuyama Y, Takao S, Aikou T. Comparison of matrix metalloproteinase expression between primary tumors with or without liver metastasis in pancreatic and colorectal carcinomas. J Surg Oncol 2002;80:105-10
17. Bodey B, Bodey B Jr, et al. Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung. In Vivo 2001;15:175-80
18. Xu L, Chen S, Bergan RC. MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer. Oncogene 2006;25:2987-98
19. Kim ES, Kim MS, Moon A. TGF-beta-induced upregulation of MMP-2 and MMP-9 depends on p38 MAPK, but not ERK signaling in MCF10A human breast epithelial cells. Int J Oncol 2004;25:1375-82
20. Shin I, Kim S, Song H, et al. H-Ras-specific activation of Rac-MKK3/ 6-p38 pathway: its critical role in invasion and migration of breast epithelial cells. J Biol Chem 2005;280:14675-83
21. Mao L, Yuan L, Slakey LM, et al. Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res 2010;12:R107
22. Lungu G, Covaleda L, Mendes O, et al. FGF-1-induced matrix metalloproteinase- 9 expression in breast cancer cells is mediated by increased activities of NFkappaB and activating protein-1. Mol Carcinog 2008;47:424-35
23. Huang S, Jiang Y, Li Z, et al. Apoptosis signaling pathway in T cells is composed of ICE/Ced-3 family proteases and MAP kinase kinase 6b. Immunity 1997;6:739-49
24. Chen H, Zhu G, Li Y, et al. Extracellular signal-regulated kinase signaling pathway regulates breast cancer cell migration by maintaining slug expression. Cancer Res 2009;69:9228-35
25. Huang S, Stupack D, Mathias P, et al. Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes. Proc Natl Acad Sci USA 1997;94:8156-61
26. Zhou QM, Wang XF, Liu XJ, et al. Curcumin improves MMC-based chemotherapy by simultaneously sensitising cancer cells to MMC and reducing MMC-associated side-effects. Eur J Cancer 2011;47:2240-7
27. Whyte J, Bergin O, Bianchi A, et al. Key signalling nodes in mammary gland development and cancer. Mitogenactivated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development. Breast Cancer Res 2009;11:209
28. Ferreiro I, Barragan M, Gubern A, et al. The p38 SAPK is recruited to chromatin via its interaction with transcription factors. J Biol Chem 2010;285:31819-28
29. Tanos T, Marinissen MJ, Leskow FC, et al. Phosphorylation of c-Fos by members of the p38 MAPK family. Role in the AP-1 response to UV light. J Biol Chem 2005;280:18842-52
30. Tsai PW, Shiah SG, Lin MT, et al. Up-regulation of vascular endothelial growth factor C in breast cancer cells by heregulin-beta 1. A critical role of p38/ nuclear factor-kappa B signaling pathway. J Biol Chem 2003;278:5750-9
31. Jemal A, Siegel R, Ward E, et al. Cancer statistics. 2008. CA Cancer J Clin 2008;58:71-96
32. Yadav DK, Kalani K, Singh AK, et al. Design, synthesis and in vitro evaluation of 18 b-glycyrrhetinic acid derivatives for anticancer activity against human breast cancer cell line MCF-7. Curr Med Chem 2014;9:1160-70
33. Yadav DK, Kalani K, Khan F, et al. QSAR and docking based semi-synthesis and in vitro evaluation of 18 bglycyrrhetinic acid derivatives against human lung cancer cell line A-549. Med Chem 2013;8:1073-84
34. Huang S, New L, Pan Z, et al. Urokinase plasminogen activator/ urokinase-specific surface receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J Biol Chem 2000;275:12266-72
35. Esteva FJ, Sahin AA, Smith TL, et al. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph nodepositive breast carcinoma. Cancer 2004;100:499-506
36. del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 2012;40:79-84
37. Behren A, Muhlen S, Acuna Sanhueza GA, et al. Phenotype-assisted transcriptome analysis identifies FOXM1 downstream from Ras-MKK3-p38 to regulate in vitro cellular invasion. Oncogene 2010;29:1519-30
38. Gomes LR, Terra LF, Wailemann RA, et al. TGF-beta1 modulates the homeostasis between MMPs and MMP inhibitors through p38 MAPK and ERK1/2 in highly invasive breast cancer cells. BMC Cancer 2012;12:26
39. Hsieh MJ, Chen KS, Chiou HL, et al. Carbonic anhydrase XII promotes invasion and migration ability of MDA-MB-231 breast cancer cells through the p38 MAPK signaling pathway. Eur J Cell Biol 2010;89:598-606
40. Kim IY, Yong HY, Kang KW, et al. Overexpression of ErbB2 induces invasion of MCF10A human breast epithelial cells via MMP-9. Cancer Lett 2009;275:227-33
41. Noh EM, Youn HJ, Jung SH, et al. Cordycepin inhibits TPA-induced matrix metalloproteinase-9 expression by suppressing the MAPK/AP-1 pathway in MCF-7 human breast cancer cells. Int J Mol Med 2010;25:255-60
42. Byun HJ, Hong IK, Kim E, et al. A splice variant of CD99 increases motility and MMP-9 expression of human breast cancer cells through the AKT-, ERK-, and JNK-dependent AP-1 activation signaling pathways. J Biol Chem 2006;281:34833-47
43. Jutooru I, Chadalapaka G, Chintharlapalli S, et al. Induction of apoptosis and nonsteroidal antiinflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Mol Carcinog 2009;48:692-702